# Transthyretin Amyloid Cardiomyopathy FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/transthyretin-amyloid-cardiomyopathy

> 2 upcoming FDA catalysts in transthyretin Amyloid Cardiomyopathy: ALXN2220 (AZN) on Dec 2027 to Mar 2028 (topline data readout); ALXN2220 (AZN) on December 2027 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 13, 2026 | [WAINUA (eplontersen) primary completion](https://sec-api.dev/pdufa/eplontersen) | AZN | Transthyretin Amyloid Cardiomyopathy | completed | "NCT06194825 (EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-05-13 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06194825)) |
| Dec 2027 to Mar 2028 | [ALXN2220 topline data readout](https://sec-api.dev/pdufa/alxn2220) | AZN | Transthyretin Amyloid Cardiomyopathy | scheduled | "NCT06183931 (Study of ALXN2220 Versus Placebo in Adults With ATTR-CM): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-12-06 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06183931)) |
| December 2027 | [ALXN2220 primary completion](https://sec-api.dev/pdufa/alxn2220) | AZN | Transthyretin Amyloid Cardiomyopathy | scheduled | "NCT06183931 (Study of ALXN2220 Versus Placebo in Adults With ATTR-CM): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-12-06 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06183931)) |

## Drugs

- [WAINUA (eplontersen)](https://sec-api.dev/pdufa/eplontersen) (AZN)
- [ALXN2220](https://sec-api.dev/pdufa/alxn2220) (AZN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/transthyretin-amyloid-cardiomyopathy.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Transthyretin Amyloid Cardiomyopathy FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/transthyretin-amyloid-cardiomyopathy

```bibtex
@misc{secapidev_indications_transthyretin_amyloid_cardiomyopathy_20261116,
  title        = {Transthyretin Amyloid Cardiomyopathy FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/transthyretin-amyloid-cardiomyopathy}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_transthyretin_amyloid_cardiomyopathy_20261116","title":"Transthyretin Amyloid Cardiomyopathy FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/transthyretin-amyloid-cardiomyopathy","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
